Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to -$414714.0.

  • Ensysce Biosciences' Net Cash Flow fell 11333.33% to -$414714.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.4 million, marking a year-over-year decrease of 18763.65%. This contributed to the annual value of $2.4 million for FY2024, which is 21750.78% up from last year.
  • Latest data reveals that Ensysce Biosciences reported Net Cash Flow of -$414714.0 as of Q3 2025, which was down 11333.33% from -$840916.0 recorded in Q2 2025.
  • Over the past 5 years, Ensysce Biosciences' Net Cash Flow peaked at $7.7 million during Q2 2021, and registered a low of -$4.7 million during Q2 2022.
  • In the last 5 years, Ensysce Biosciences' Net Cash Flow had a median value of -$449586.0 in 2025 and averaged $84349.8.
  • In the last 5 years, Ensysce Biosciences' Net Cash Flow plummeted by 409505.19% in 2022 and then skyrocketed by 23168.75% in 2024.
  • Over the past 5 years, Ensysce Biosciences' Net Cash Flow (Quarter) stood at $5.4 million in 2021, then crashed by 125.01% to -$1.4 million in 2022, then skyrocketed by 74.86% to -$340777.0 in 2023, then tumbled by 91.19% to -$651515.0 in 2024, then soared by 36.35% to -$414714.0 in 2025.
  • Its last three reported values are -$414714.0 in Q3 2025, -$840916.0 for Q2 2025, and -$449586.0 during Q1 2025.